Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions

12 listopada 2026 zaktualizowane przez: Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions in Chinese Participants Undergoing Allergy Testing

This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

650

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Beijing, Chiny, 100730
        • Beijing Tongren Hospital, Capital Medical University
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Chiny, 430030
        • Tongji Hospital, Tongji Medical College of Hust
        • Kontakt:
    • Shanxi
      • Taiyuan, Shanxi, Chiny, 030032
        • Shanxi Bethune Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 60 lat (Dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Male or female participants aged 18-60 years, inclusive.
  2. Participants with a current or previous history of allergic diseases, such as allergic rhinitis, allergic conjunctivitis, or allergic asthma.
  3. Participants who are able to understand the study and voluntarily provide written informed consent.

Exclusion Criteria:

  1. History of needle-related syncope or vasovagal reactions to the sight of blood.
  2. Pregnant or breastfeeding women.
  3. History of malignant tumors.
  4. Currently receiving beta-blockers or angiotensin-converting enzyme inhibitors and unable to discontinue treatment during the study.
  5. Currently experiencing a severe allergic reaction or having a history of severe allergic reactions, including generalized urticaria, severe or more serious acute asthma exacerbations, or anaphylactic shock.
  6. Use of topical corticosteroids or topical calcineurin inhibitors at the intended skin prick site within 7 days before SPT.
  7. Systemic use of antihistamines or antihistamine-containing combination medications before SPT, with a discontinuation period not exceeding five elimination half-lives of the antihistamine.
  8. Use of short-acting systemic corticosteroids within 2 days, intermediate-acting systemic corticosteroids within 5 days, or long-acting systemic corticosteroids within 12 days before SPT.
  9. Systemic use of immunosuppressants within 14 days before SPT.
  10. Use of phenothiazine antipsychotics within 10 days or imipramine-class antidepressants within 21 days before SPT.
  11. Treatment with dupilumab or similar agents within 3 months before SPT.
  12. Treatment with omalizumab or similar agents within 5 months before SPT.
  13. Photochemotherapy on the volar surfaces of both forearms within 30 days before SPT.
  14. Skin infection, dermatitis, trauma, scarring, pigmentation, or other pathological changes at the intended volar forearm test site that, in the investigator's judgment, may interfere with SPT interpretation.
  15. Positive skin scratch test for dermographism during screening.
  16. Participation in another drug clinical trial with administration of an investigational product within 1 month before screening, or less than five elimination half-lives since the last administration of that investigational product, whichever period is longer.
  17. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Diagnostyczny
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Skin Prick Test Group

All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Sensitivity: Ragweed Pollen (3,500 DU/mL)
Ramy czasowe: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Ragweed Pollen (3,500 DU/mL)
Ramy czasowe: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a negative SPT result among participants with serum ragweed sIgE <0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (19,500 DU/mL)
Ramy czasowe: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (19,500 DU/mL)
Ramy czasowe: 15-20 minutes after skin prick testing (Day 1).

Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (39,000 DU/mL)
Ramy czasowe: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (39,000 DU/mL)
Ramy czasowe: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Adverse Events
Ramy czasowe: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.

Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable.

From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
Changes in Vital Signs from Baseline
Ramy czasowe: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.

Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
Changes in Physical Examination Findings from Baseline
Ramy czasowe: At screening and on Day 2 of the study or at early termination.

Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.
Changes in Hematology Parameters from Baseline
Ramy czasowe: At screening and on Day 2 of the study or at early termination.

Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.
Changes in Urinalysis Parameters from Baseline
Ramy czasowe: At screening and on Day 2 of the study or at early termination.

Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

11 listopada 2026

Zakończenie podstawowe (Szacowany)

1 czerwca 2027

Ukończenie studiów (Szacowany)

1 października 2027

Daty rejestracji na studia

Pierwszy przesłany

5 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 listopada 2026

Pierwszy wysłany (Rzeczywisty)

18 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

12 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • WOLWO-D1-0III32-1

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj